Chemosensitivity and chemoresistance testing in ovarian cancer

Current Opinion in Obstetrics and Gynecology

Volumn 21, Issue 1, 2009, Pages 39-43

  Cree, Ian A ^a  

^a QUEEN ALEXANDRA HOSPITAL   (United Kingdom)

Author keywords

Assay; Chemoresistance; Chemosensitivity; Ovarian cancer

Indexed keywords

PLATINUM COMPLEX; TRASTUZUMAB;

BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CANCER SURVIVAL; CHEMOSENSITIVITY; CLINICAL ASSESSMENT; GENETIC ANALYSIS; HUMAN; OVARY CANCER; PRIORITY JOURNAL; REVIEW; STEM CELL;

ADENOSINE TRIPHOSPHATE; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HUMANS; OVARIAN NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TUMOR MARKERS, BIOLOGICAL;

EID: 59149093636     PISSN: 1040872X     EISSN: None     Source Type: Journal    
DOI: 10.1097/GCO.0b013e32832210ff     Document Type: Review

References (25)

1. Hamburger AW, Salmon SE. Primary bioassay of human tumor stem cells. Science 1977; 197:461-463.
2. Fruehauf JP. In vitro assay-assisted treatment selection for women with breast or ovarian cancer. Endocr Relat Cancer 2002; 9:171 -182.
3. Zhang S, Balch C, Chan MW, et al., Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer research 2008; 68:4311-4320.
4. Glinsky GV. Stemness' genomics law governs clinical behavior of human cancer: implications for decision making in disease management. J Clin Oncol 2008; 26:2846-2853.
5. Santillan A, Kim YW, Zahurak ML, et al., Differences of chemoresistance assay between invasive micropapillary/low-grade serous ovarian carcinoma and high-grade serous ovarian carcinoma. Int J Gynecol Cancer 2007; 17:601-606.
6. Andreotti PE, Cree IA, Kurbacher CM, et al., Chemosensitivity testing of human tumors using a microplate adenosine triphosphate luminescence assay: clinical correlation for cisplatin resistance of ovarian carcinoma. Cancer Res 1995; 55:5276-5282.
7. Cree IA. Luminescence-based cell viability testing. Methods Mol Biol 1998; 102:169-177.
8. Fernando A, Glaysher S, Conroy M, et al., Effect of culture conditions on the chemosensitivity of ovarian cancer cell lines. Anticancer Drugs 2006; 17:913-919.
9. Gallion H, Christopherson WA, Coleman RL, et al., Progression-free interval in ovarian cancer and predictive value of an ex vivo chemoresponse assay. Int J Gynecol Cancer 2006; 16:194-201.
10. Han SS, Choi SH, Lee YK, et al., Predictive value of individualized tumor response testing by ATP-based chemotherapy response assay in ovarian cancer. Cancer Invest 2008; 26:426-430.
11. Kurbacher CM, Cree IA, Bruckner HW, et al., Use of an ex vivo ATP luminescence assay to direct chemotherapy for recurrent ovarian cancer. Anticancer drugs 1998; 9:51 -57.
12. Cree IA, Kurbacher CM, Lamont A, et al., A prospective randomized controlled trial of tumour chemosensitivity assay directed chemotherapy versus physician's choice in patients with recurrent platinum-resistant ovarian cancer. Anticancer Drugs 2007; 18:1093-1101. This is the first trial of chemosensitivity assay-directed chemotherapy to be comleted.
13. Sharma S, Neale MH, Di Nicolantonio F, et al., Outcome of ATP-based tumor chemosensitivity assay directed chemotherapy in heavily pretreated recurrent ovarian carcinoma. BMC Cancer 2003; 3:19.
14. Neubauer H, Stefanova M, Solomayer E, et al., Predicting resistance to platinum-containing chemotherapy with the ATP tumor chemosensitivity assay in primary ovarian cancer. Anticancer Res 2008; 28:949-955. This study provides independent validation of the earlier study by Konecny and coworkers, suggesting that the ATP-TCA can predict sensitivity to different chemotherapy agents reliably in untreated ovarian cancer.
15. Umezu T, Shibata K, Kajiyama H, et al., Taxol resistance among the different histological subtypes of ovarian cancer may be associated with the expression of class III beta-tubulin. Int J Gynecol Pathol 2008; 27: 207-212. One of two recent papers suggesting that taxane resistance may be linked to tubulin expression. This remains controversial, and the significance of the findings is difficult to assess until further research available in abstract from several groups is ublished.
16. Tommasi S, Mangia A, Lacalamita R, et al., Cytoskeleton and paclitaxel sensitivity in breast cancer: the role of beta-tubulins. Int J Cancer 2007; 120:2078-2085.
17. Huang Y. Pharmacogenetics/genomics of membrane transporters in cancer chemotherapy. Cancer Metastasis Rev 2007; 26:183-201.
18. He X, Lin B, Kong L, Zhang J. The potential mechanism of chemosensitive difference between 2 types of ovarian cancer. Saudi Med J 2007; 28:1044- 1049.
19. O'Toole SA, Sheppard BL, Laios A, et al., Potential predictors of chemotherapy response in ovarian cancer-how do we define chemosensitivity? Gynecol Oncol 2007; 104:345-351.
20. Naniwa J, Kigawa J, Kanamori Y, et al., Genetic diagnosis for chemosensitivity with drug-resistance genes in epithelial ovarian cancer. Int J Gynecol Cancer 2007; 17:76-82. An excellent paper showing that hypothesis-driven research can pay dividends if linked with robust technology such as quantitative RT-PCR. This study shows that a relatively small number of genes involved in drug resistance and sensitivity can predict patient response to chemotherapy.
21. Zhang JT. Use of arrays to investigate the contribution of ATP-binding cassette transporters to drug resistance in cancer chemotherapy and prediction of chemosensitivity. Cell Res 2007; 17:311 -323.
22. Tetu B, Popa I, Bairati I, L'Esperance S, et al., Immunohistochemical analysis of possible chemoresistance markers identified by micro-arrays on serous ovarian carcinomas. Mod Pathol 2008; 21:1002-1010. An alternative to PCR validation of markers found by pan-genomic expression studies remains immunohistochemistry. However, unlike PCR, immunohistochemistry is difficult to quantitate reliably and it is likely that PCR methods will be preferred by many.
23. Tuefferd M, Couturier J, Penault-Llorca F, et al., HER2 status in ovarian carcinomas: a mutticenter GINECO study of 320 patients. PLoS ONE 2007; 2:e1138.
24. Sargent DJ, Conley BA, Allegra C, Collette L. Clinical trial designs for predictive marker validation in cancer treatment trials. J Clin Oncol 2005; 23:2020-2027.
25. Di Nicolantonio F, Mercer SJ, Knight LA, et al., Cancer cell adaptation to chemotherapy. BMC Cancer 2005; 5:78.